|Preexposure prophylaxis for HIV infection among African women|
L Van Damme, A Corneli, K Ahmed, K Agot, J Lombaard, S Kapiga, ...
New England Journal of Medicine 367 (5), 411-422, 2012
|Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy|
NM Archin, AL Liberty, AD Kashuba, SK Choudhary, JD Kuruc, ...
Nature 487 (7408), 482-485, 2012
|Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method|
V ÷zdemir, W Kalow, BK Tang, AD Paterson, SE Walker, L Endrenyi, ...
Pharmacogenetics and Genomics 10 (5), 373-388, 2000
|Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria|
ADM Kashuba, AN Nafziger, GL Drusano, JS Bertino
Antimicrobial agents and chemotherapy 43 (3), 623-629, 1999
|An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients|
CA Spina, J Anderson, NM Archin, A Bosque, J Chan, M Famiglietti, ...
PLoS Pathog 9 (12), e1003834, 2013
|Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1|
MS Cohen, C Gay, ADM Kashuba, S Blower, L Paxton
Annals of internal medicine 146 (8), 591-601, 2007
|Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission|
KB Patterson, HA Prince, E Kraft, AJ Jenkins, NJ Shaheen, JF Rooney, ...
Science translational medicine 3 (112), 112re4-112re4, 2011
|Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?|
MS Cohen, MK Smith, KE Muessig, TB Hallett, KA Powers, AD Kashuba
The Lancet 382 (9903), 1515-1524, 2013
|Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women|
SSA Karim, ADM Kashuba, L Werner, QA Karim
The Lancet 378 (9787), 279-281, 2011
|HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat|
NM Archin, R Bateson, MK Tripathy, AM Crooks, KH Yang, NP Dahl, ...
The Journal of infectious diseases 210 (5), 728-735, 2014
|Antiretroviral drug exposure in the female genital tract: implications for oral pre-and post-exposure prophylaxis|
JB Dumond, RF Yeh, KB Patterson, AH Corbett, BH Jung, NL Rezk, ...
AIDS (London, England) 21 (14), 1899, 2007
|Updated guideline to perform therapeutic drug monitoring for antiretroviral agents.|
CJL La Porte, D Back, T Blaschke, CAB Boucher, CV Fletcher, C Flexner, ...
|Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography–tandem mass spectrometry|
BH Jung, NL Rezk, AS Bridges, AH Corbett, ADM Kashuba
Biomedical Chromatography 21 (10), 1095-1104, 2007
|Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1|
ADM Kashuba, JR Dyer, LM Kramer, RH Raasch, JJ Eron, MS Cohen
Antimicrobial agents and chemotherapy 43 (8), 1817-1826, 1999
|Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by†…|
RF Yeh, VE Gaver, KB Patterson, NL Rezk, F Baxter-Meheux, MJ Blake, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 42 (1), 52-60, 2006
|Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel|
M Cranage, S Sharpe, C Herrera, A Cope, M Dennis, N Berry, C Ham, ...
PLoS Med 5 (8), e157, 2008
|Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs|
ADM Kashuba, AN Nafziger
Clinical pharmacokinetics 34 (3), 203-218, 1998
|Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir|
ML Cottrell, T Hadzic, ADM Kashuba
Clinical pharmacokinetics 52 (11), 981-994, 2013
|Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N‐acetyltransferase‐2, and xanthine oxidase activities with the†…|
S Chainuvati, AN Nafziger, JS Leeder, A Gaedigk, GL Kearns, E Sellers, ...
Clinical pharmacology & therapeutics 74 (5), 437-447, 2003
|A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without†…|
ML Cottrell, KH Yang, HMA Prince, C Sykes, N White, S Malone, ...
The Journal of infectious diseases 214 (1), 55-64, 2016